Stockscreener 앱 받기
57.59
2.51%
-1.48
시장 영업 전:
57.71
0.12
+0.21%
전일 마감가:
$59.07
열려 있는:
$58.91
하루 거래량:
1.53M
Relative Volume:
1.82
시가총액:
$3.16B
수익:
$1.39B
순이익/손실:
$-242.49M
주가수익비율:
-12.87
EPS:
-4.4759
순현금흐름:
$173.29M
1주 성능:
-6.04%
1개월 성능:
-9.72%
6개월 성능:
+13.34%
1년 성능:
+58.74%
1일 변동 폭
$56.44
$59.26
1주일 범위
$56.44
$61.36
52주 변동 폭
$35.00
$71.92
Livanova Plc Stock (LIVN) Company Profile
명칭
Livanova Plc
전화
4402033250662
주소
20 EASTBOURNE TERRACE, LONDON
Compare LIVN vs ABT, SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LIVN
Livanova Plc
|
57.59 | 3.16B | 1.39B | -242.49M | 173.29M | -4.4759 |
ABT
Abbott Laboratories
|
87.17 | 151.83B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
295.25 | 113.08B | 25.27B | 3.34B | 4.57B | 8.6358 |
MDT
Medtronic Plc
|
77.79 | 99.87B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
55.98 | 83.21B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
82.91 | 47.80B | 6.30B | 1.07B | 1.34B | 1.8406 |
Livanova Plc Stock (LIVN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-19 | 개시 | KeyBanc Capital Markets | Overweight |
| 2025-10-01 | 다운그레이드 | Goldman | Buy → Neutral |
| 2025-05-20 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2025-02-26 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2024-10-04 | 개시 | Goldman | Buy |
| 2024-09-17 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2024-03-20 | 재확인 | Needham | Buy |
| 2024-02-20 | 업그레이드 | Mizuho | Neutral → Buy |
| 2023-09-06 | 개시 | HSBC Securities | Hold |
| 2023-07-19 | 개시 | Robert W. Baird | Neutral |
| 2023-04-14 | 개시 | Mizuho | Neutral |
| 2022-12-21 | 개시 | Barclays | Equal Weight |
| 2022-04-06 | 개시 | Wolfe Research | Outperform |
| 2022-02-24 | 업그레이드 | UBS | Neutral → Buy |
| 2021-12-03 | 개시 | Goldman | Buy |
| 2021-08-20 | 재확인 | Needham | Buy |
| 2021-07-20 | 업그레이드 | Needham | Hold → Buy |
| 2021-03-03 | 다운그레이드 | Berenberg | Buy → Hold |
| 2021-01-05 | 다운그레이드 | Needham | Buy → Hold |
| 2020-09-02 | 개시 | Robert W. Baird | Outperform |
| 2020-06-26 | 재확인 | Needham | Buy |
| 2019-10-30 | 재확인 | Needham | Buy |
| 2019-02-28 | 재확인 | Needham | Buy |
| 2018-11-28 | 개시 | UBS | Neutral |
| 2018-08-02 | 재확인 | Needham | Buy |
| 2018-06-08 | 개시 | Stifel | Buy |
| 2018-05-31 | 재확인 | Needham | Buy |
| 2018-02-28 | 재확인 | Needham | Buy |
모두보기
Livanova Plc 주식(LIVN)의 최신 뉴스
MSN Money - MSN
LivaNova earnings ahead as reimbursement tailwinds build By Investing.com - Investing.com Nigeria
Avoiding Lag: Real-Time Signals in (LIVN) Movement - Stock Traders Daily
LivaNova (LIVN) Projected to Post Earnings on Wednesday - MarketBeat
LivaNova PLC (LIVN) Shares Fall 3.3% -- GF Value Says Still Over - GuruFocus
LivaNova gains FDA premarket approval for Aura6000 for sleep apnea - MSN
Will OSPREY Trial Data on aura6000 Sleep Apnea Device Change LivaNova's (LIVN) Narrative - simplywall.st
Peregrine Capital Management LLC Invests $3.83 Million in LivaNova PLC $LIVN - MarketBeat
LivaNova (NASDAQ:LIVN) Shares Cross Below 50 Day Moving AverageHere's Why - MarketBeat
Global Perfusion Systems Market to Register Incremental Growth at a CAGR of ~5% by 2034 | DelveInsight - GlobeNewswire Inc.
Neurostimulation Devices Market to Reach USD 17.82 Billion - openPR.com
Discipline and Rules-Based Execution in LIVN Response - Stock Traders Daily
Annals of Internal Medicine Publishes 12-Month Results from LivaNova’s OSPREY Clinical Study for Obstructive Sleep Apnea - BioSpace
LivaNova PLC stock (US5356991077): Why does its medtech innovation edge matter more now? - AD HOC NEWS
Tissue Heart Valves Market Key Companies AnalysisEdwards - openPR.com
LivaNova PLC (NASDAQ:LIVN) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Best Time to Sell LivaNova PLC (LIVN) Stock (Institutional Selling) 2026-04-16Insider Selling - Xã Châu Thành
In-Line Blood Monitoring Devices Market to Reach USD 0.42 - openPR.com
33,332 Shares in LivaNova PLC $LIVN Acquired by Tudor Investment Corp ET AL - MarketBeat
Behavioral Patterns of LIVN and Institutional Flows - Stock Traders Daily
Nasdaq Moves: Whats the fair value of LivaNova PLC stockMarket Performance Recap & Weekly Momentum Stock Picks - baoquankhu1.vn
Aberdeen Group plc Lowers Stock Holdings in LivaNova PLC $LIVN - MarketBeat
Market Catalysts: Is LivaNova PLC stock a falling knife or bargain buy2026 Trends & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
LivaNova PLC (LIVN) Stock Forecasts - Yahoo Finance
Allspring Global Investments Holdings LLC Reduces Stake in LivaNova PLC $LIVN - MarketBeat
Exchange Traded Concepts LLC Buys New Shares in LivaNova PLC $LIVN - MarketBeat
LivaNova PLC (LIVN) Stock forecasts - Yahoo Finance UK
LivaNova to present at JP Morgan Healthcare Conference in January - MSN
(LIVN) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Aug Macro: Does LivaNova PLC stock benefit from AI growth2026 Earnings & Daily Volume Surge Signals - baoquankhu1.vn
Tudor Investment Corp ET AL Acquires Shares of 33,332 LivaNova PLC - National Today
Tudor Investment Corp ET AL Acquires Shares of 33,332 LivaNova PLC $LIVN - marketbeat.com
How FDA Approval of Aura6000 Sleep Apnea Therapy Will Impact LivaNova (LIVN) Investors - Sahm
Should FDA Approval of aura6000 Sleep Apnea Therapy Require Action From LivaNova (LIVN) Investors? - Yahoo Finance
LivaNova (LIVN) Announces FDA Approval of aura6000 System for Obstructive Sleep Apnea - Insider Monkey
LivaNova Broadens OSA Treatment Options With FDA Clearance for aura6000 System - Bitget
LivaNova Expands OSA Care With FDA-Approved aura6000 System - Yahoo Finance
LivaNova to Announce First-Quarter 2026 Results - Business Wire
LivaNova PLC stock faces analyst scrutiny amid mixed ratings and modest growth outlook in medical de - AD HOC NEWS
LivaNova PLC (LIVN) Stock Analysis: Evaluating a 26% Upside Potential in the Medical Device Sector - DirectorsTalk Interviews
LivaNova PLC (NASDAQ:LIVN) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
FDA Approves Hypoglossal Nerve Stimulation Device for OSA - Medical Dialogues
FDA Approves LivaNova’s aura6000 Neurostimulator for OSA - Sleep Review
LivaNova aura6000 Obstructive Sleep Apnea treatment granted FDA premarket approval - Med-Tech Insights
LivaNova eyes 2027 launch of neural sleep apnoea therapy after FDA approval - Medical Device Network
Livanova Plc (LIVN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.41%
0.93%
자본화:
|
볼륨(24시간):